Raw Materials & Excipients Management – Page 37

Supplier nitrosamine control weak during supplier audit – risk mitigation and control strategy

Recognizing symptoms indicative of weak nitrosamine control during audits is crucial. Below are operational signals that may indicate underlying issues:Click to read the full article.

FIFO not followed during inspection walkthrough – preventing repeat storage deviations

Symptoms of FIFO not being followed may manifest in various ways, including:Click to read the full article.

Potential nitrosamine source identified during submission support – risk mitigation and control strategy

Identifying the right signals early can help contain nitrosamine risks effectively. The following symptoms are often observed:Click to read the full article.

Environmental monitoring gaps during inspection walkthrough – product quality impact assessment

In any pharmaceutical manufacturing or laboratory environment, the detection of environmental monitoring gaps can manifest as various signals. Early detection is critical in managing these occurrences effectively. Common symptoms include:Click…

Risk mitigation plan inadequate during ongoing surveillance – inspection-ready justification

Recognizing signals indicative of inadequate risk mitigation is the first step in managing potential issues surrounding nitrosamine contamination and raw material quality. Key symptoms to watch for include:Click to read…

FIFO not followed during inspection walkthrough – GMP storage compliance requirements

The initial identification of the issue typically involves various signals that suggest non-compliance with FIFO practices:Click to read the full article.

Nitrosamine risk assessment incomplete during risk assessment – preventing product recall

How to Address Incomplete Nitrosamine Risk Assessments to Prevent Product Recalls In recent years, the pharmaceutical industry has faced significant scrutiny concerning the presence of nitrosamines in drug products, stemming…

FIFO not followed during routine checks – GMP storage compliance requirements

Identifying the symptoms of FIFO non-compliance is the first step in addressing the issue. Potential indicators can include:Click to read the full article.

Nitrosamine risk assessment incomplete during ongoing surveillance – FDA/EMA nitrosamine expectations

Identifying early warning signs is crucial in managing nitrosamine risk. Symptoms of an incomplete risk assessment may manifest in various ways across the manufacturing floor and quality control (QC) labs:Click…

FIFO not followed during deviation investigation – preventing repeat storage deviations

When FIFO adherence is compromised, several symptoms may be noticed on the manufacturing floor or in quality control labs. These signals can manifest in various forms:Click to read the full…

Potential nitrosamine source identified during risk assessment – risk mitigation and control strategy

Identifying symptoms related to nitrosamine contamination requires vigilance and acute awareness among all personnel involved in pharmaceutical manufacturing. Symptoms can manifest in various ways:Click to read the full article.

Improper segregation of materials during inventory reconciliation – inspection defense documentation

Material Mismanagement during Inventory Reconciliation: A Detailed Investigation Protocol In the realm of pharmaceutical manufacturing, maintaining rigorous control over raw materials is crucial for ensuring product quality and compliance with…